Open Nav

Kedalion Therapeutics, Inc.

  • Peter Noymer, Kedalion Therapeutics, Inc.

investor outreach

  • Date:Wednesday, October 17
  • Time:3:45 PM - 4:00 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream(TM) platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with up to an 80% reduction in dose compared to standard eye drops. Efficacy, along with substantially reduced side effects and improved comfort, were all demonstrated in two Phase 1 studies in patients for two different drug classes. Kedalion’s products will leverage the FDA’s 505(b)(2) regulatory pathway to quickly and efficiently bring to market these novel therapies. The company closed a $5 million Series A round in July 2018 to further advance the AcuStream technology and to support additional clinical trials. Kedalion is based in Menlo Park, CA. For more information, visit
  • Company
  • Company HQ City:Menlo Park
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Peter Noymer, PhD
  • Year Founded:2016
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development :latanoprost
  • Development Phase of Primary Product:Phase I
  • Size of Last Investment Round:$5 million
  • Total Amount Raised to Date, In All Rounds:$9.5 million
Peter Noymer
Kedalion Therapeutics, Inc.